Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment (2016)

Historic Asset Writedowns and Impairment for Amphastar Pharmaceuticals (AMPH) over the last 4 years, with Q2 2016 value amounting to $114000.0.

  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $114000.0 in Q2 2016 from the same period last year, while for Dec 2023 it was $114000.0, marking a year-over-year change of. This contributed to the annual value of $2.7 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Asset Writedowns and Impairment of $114000.0 as of Q2 2016.
  • Amphastar Pharmaceuticals' 5-year Asset Writedowns and Impairment high stood at $217000.0 for Q1 2016, and its period low was $4000.0 during Q3 2015.
  • Its 4-year average for Asset Writedowns and Impairment is $113555.6, with a median of $120000.0 in 2013.
  • Examining YoY changes over the last 5 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment showed a top increase of 6410.26% in 2015 and a maximum decrease of 6923.08% in 2015.
  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $120000.0 in 2013, then plummeted by 35.0% to $78000.0 in 2014, then soared by 64.1% to $128000.0 in 2015, then dropped by 10.94% to $114000.0 in 2016.
  • Its Asset Writedowns and Impairment was $114000.0 in Q2 2016, compared to $217000.0 in Q1 2016 and $128000.0 in Q4 2015.